Skinfluenced - The Skin Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Skinfluenced - The Skin Podcast

Health & Fitness

Frequency: 1 episode/7d. Total Eps: 14

🧴 Harnessing the power of technology, Skinfluenced: The Skin Podcast keeps you plugged into the fast-moving worlds of dermatology, wellness, and aesthetics. From the latest journal articles and groundbreaking studies, to new FDA approvals, new product launches, and clinical insights—this podcast is your go-to source for evidence-based updates that matter. Whether you're a seasoned provider or just dipping your toe in the sand, you'll stay one step ahead of the trends, the science, and your skin. Disclaimer: All content is for educational purposes only and does not constitute medical advice.

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇫🇷 France - medicine
28/10/2025
#85
🇫🇷 France - medicine
27/10/2025
#62

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 52%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Press Release: Libtayo (Cemiplimab) Approved as First Adjuvant Immunotherapy for High-Risk cSCC

Season 1 · Episode 14

Thursday, October 23, 2025 • Duration 14:50

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s recent approval of Libtayo® (Cemiplimab-rwlc) as the first and only adjuvant immunotherapy for patients with high-risk cutaneous squamous cell carcinoma (cSCC) following surgery and radiation.

Join us as we discuss:🧬 The pivotal trial showing improved disease-free survival in high-risk cSCC💉 The evolving role of PD-1 blockade in post-surgical skin cancer management🧠 How this approval changes the treatment landscape for patients at risk of recurrence

This landmark decision represents a major step forward in skin cancer care—bringing immunotherapy into the adjuvant setting and offering new hope for patients facing aggressive or recurrent cSCC.

Link to Source(s):

American Association for Cancer Research. Immunotherapy Approved for Preventing Recurrence of Certain Skin Cancers. Accessed October 22, 2025. https://tinyurl.com/ywpynwfn

American Journal of Managed Care. FDA Approves Cemiplimab as First & Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/5b4s6jb7

Dermatology Advisor. FDA Approves Libtayo for Adjuvant Treatment of High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/58h5cckn

Derm Digest. FDA Approves Cemiplimab to Treat cSCC With High Risk of Recurrence After Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/2s9jjc53

Journal of Clinical Oncology. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Patients With High-Risk Cutaneous Squamous Cell Carcinoma. Published 2025; 43(16_suppl):6000. Accessed October 22, 2025. https://tinyurl.com/27ekuzch

New England Journal of Medicine. Adjuvant Cemiplimab for Cutaneous Squamous-Cell Carcinoma. Published 2025. Accessed October 22, 2025. https://tinyurl.com/4rynuvky

OncLive. Dr. Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma. Accessed October 22, 2025. https://tinyurl.com/4kvzbv8z

Oncology Nursing Society. FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma. Published October 2025. Accessed October 22, 2025. https://tinyurl.com/4ne9rsv3

Regeneron Pharmaceuticals. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Phase 3 Trial. Accessed October 22, 2025. https://tinyurl.com/3a9m5u6c

Regeneron Pharmaceuticals. FDA Approves Libtayo (cemiplimab-rwlc) in the U.S. as the First and Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/2hfs59k2

Regeneron Pharmaceuticals. Libtayo (cemiplimab) Phase 3 Data: Adjuvant Treatment Post-Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/yx5xkzcr

Regeneron Pharmaceuticals. Libtayo Full Prescribing Information. Accessed October 22, 2025. https://tinyurl.com/86w7ydjn

Regeneron Pharmaceuticals. Libtayo Medication Guide. Accessed October 22, 2025. https://tinyurl.com/432jx77u

ScienceDirect. Induction of Natural Cytotoxicity by Interferon: Studies on the Mechanism of Action. Trends in Biochemical Sciences. Published 1985. Accessed October 22, 2025. https://tinyurl.com/589swev2

#SCC #skincancer #skincancertreatment #Dermatology #SkinHealth #NewTreatments #FDAApproved #Therapies #ClinicalGuidelines #FDAApproval #SkinScience #EvidenceBasedMedicine #SCCManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Read moreCollapse

Press Release: Novel New Oral Treatment Option for Plaque Psoriasis

Season 1 · Episode 2

Friday, August 1, 2025 • Duration 10:07

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we review Johnson & Johnson’s recent announcement seeking FDA approval for Icotrokinra — a promising new oral medication designed to revolutionize treatment for adults and adolescents with active, moderate-to-severe Plaque Psoriasis.

Tune in to learn how this novel oral IL-23 medication works, its potential to offer a novel approach in managing inflammation and safety data, and what this could mean for patients struggling with moderate-to-severe plaque psoriasis who need new treatment options beyond current therapies.

We’ll break down the drug’s mechanism, the clinical data that supports its use, and how it fits into the evolving landscape of dermatologic care.

Link to Source(s):

Johnson & Johnson Seeks First icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigmfor Adults and Adolescents With Plaque Psoriasis: https://s203.q4cdn.com/636242992/files/doc_news/Johnson--Johnson-seeks-first-icotrokinra-U-S--FDA-approval-aiming-to-revolutionize-treatment-paradigm-for-adults-and-adolescents-with-ABQBI.pdf

#PlaquePsoriasis #Psoriasis #Icotrokinra #IL23Inhibitor #IL23 #NPF #JohnsonAndJohnson #InflammatorySkinDisease #OralTherapiesForPsO #ChronicSkinDisease #BiologicAlternatives #NewFDADrugApproval #SkinBarrierRepair #SkinScience #Dermatology #DermatologyProvider #CosmeticDermatology #Aesthetics #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast

Can TSC Calm Retinoid Irritation? A Deep Dive into the 2025 Pilot Study

Season 1 · Episode 1

Monday, July 28, 2025 • Duration 10:03

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we take a closer look at a newly published pilot study from the Journal of Cosmetic Dermatology (Feb 2025) that explores whether Tetramethylhexadecenyl Succinoyl Cysteine (TSC) — the active ingredient in Epicutis’ Lipid Serum — can help reduce the irritation commonly associated with tretinoin use.

Tune in to find out what happens when TSC is used in conjunction with tretinoin, and result are seen within just five days! The findings raise interesting questions about the future of barrier-supportive actives in dermatologic therapy.

Link to Source(s):

Pilot Study Demonstrates Tetramethylhexadecenyl Succinoyl Cysteine (TSC) Reduces Tretinoin‑Induced Erythema and Dryness in Human Subjects: https://www.researchgate.net/publication/388790490_Pilot_Study_Demonstrates_Tetramethylhexadecenyl_Succinoyl_Cysteine_TSC_Reduces_Tretinoin-Induced_Erythema_and_Dryness_in_Human_Subjects

Link to Products Discussed in Episode:

https://epicutis.com/products/lipid-serum

#RetinoidIrritation #TretinoinTips #Epicutis #LipidSerum #TSCskincare #BarrierRepair #MedicalGradeSkincare #SensitiveSkinSolutions #AcneCare #AntiAgingSkincare #TSC #SkinScience #Dermatology #DermatologyProvider #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast

Press Release: FDA Approves Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria

Season 1 · Episode 10

Thursday, October 2, 2025 • Duration 13:31

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today’s episode.

In this episode of Skinfluenced: The Skin Podcast, we review the FDA’s September 30, 2025 approval of remibrutinib (Rhapsido, Novartis), the first oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). We’ll walk through the press releases, clinical trial data, and recent publications highlighting its efficacy, safety, and potential impact on treatment pathways for CSU.

Link to Source(s):

The American Journal of Managed Care (AJMC). FDA Approves Remibrutinib for Chronic Spontaneous Urticaria. Published September 30, 2025. Accessed October 1, 2025. https://www.ajmc.com/view/fda-approves-remibrutinib-for-chronic-spontaneous-urticaria

BioSpace. Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives. Published September 30, 2025. Accessed October 1, 2025. https://www.biospace.com/fda/novartis-secures-first-fda-approval-of-oral-btk-inhibitor-for-chronic-hives

ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of Remibrutinib in Participants With Chronic Spontaneous Urticaria (NCT05030311). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05030311

ClinicalTrials.gov. A Study of Remibrutinib in Chronic Spontaneous Urticaria (NCT05032157). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05032157

Novartis. Novartis Receives FDA Approval for Rhapsido (Remibrutinib), the Only Oral Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU). Published September 30, 2025. Accessed October 1, 2025.

Press Release: Opzelura (ruxolitinib) 2% Cream Approved for Atopic Dermatitis in Ages 2 and Up

Season 1 · Episode 11

Sunday, September 21, 2025 • Duration 14:48

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we review the brand new FDA approval of Opzelura® (ruxolitinib) cream 1.5% for children ages 2 and up with atopic dermatitis. This marks a major step forward in pediatric dermatology, offering the first topical JAK inhibitor option for younger patients with mild-to-moderate AD who need more than topical steroids or topical calcineurin inhibitors.

We’ll discuss the clinical trial data from the TRuE-AD program, safety considerations, and where ruxolitinib cream may fit into the evolving treatment landscape for pediatric eczema. Tune in to learn what this means for providers, patients, and families navigating chronic AD care.

#AtopicDermatitis #Eczema #PediatricDermatology #Opzelura #Ruxolitinib #JAKInhibitor #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #ClinicalGuidelines #FDAApproval #EczemaTreatment #ADUpdate #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Business Wire. Incyte Announces U.S. FDA Approval of Opzelura (Ruxolitinib) Cream, a Topical JAK Inhibitor, for Treatment of Atopic Dermatitis (AD). Published September 21, 2021. Accessed September 20, 2025. ⁠https://www.businesswire.com/news/home/20210921006072/en/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD⁠

2025 Updated Guidelines of Care for the Management of Atopic Dermatitis in Adults

Season 1 · Episode 10

Monday, September 15, 2025 • Duration 17:06

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we’re breaking down the American Academy of Dermatology’s June 2025 focused update on the management of Atopic Dermatitis (AD) in adults.

We’ll highlight how to integrate the latest high-quality evidence into practice, including new FDA-approved therapies that are reshaping the treatment landscape. From tapinarof and roflumilast creams, to biologics like lebrikizumab and nemolizumab, we review the data behind their efficacy and safety, drawn from multiple randomized controlled trials.

You’ll also learn how these treatments fit within current regimens—whether used alone or in combination—so you can deliver the most accurate, evidence-based care for your AD patients.
#AtopicDermatitis #Eczema #ADGuidelines #AADGuidelines #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #SystemicTherapies #Lebrikizumab #Nemolizumab #Tapinarof #Roflumilast #Biologics #ClinicalGuidelines #EvidenceBasedMedicine #AADUpdate2025 #AdultAD #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Focused Update: Guidelines of Care for the Management of Atopic Dermatitis in Adults. Davis, Dawn M.R. et al. Journal of the American Academy of Dermatology, Volume 93, Issue 3, 745.e1 - 745.e7 https://www.jaad.org/article/S0190-9622(25)02125-5/fulltext

Just Released! Is PDGF Safe?

Season 1 · Episode 9

Tuesday, September 9, 2025 • Duration 18:39

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we have a brand new article to report on. Just a few days ago, a review of the safety of Platelet-Derived Growth Factor (PDGF) was released. Tune in to learn all about this topic of immense interest recently, as well as it’s importance in aesthetic and regenerative medicine.

This white paper highlights over 25 years of extensive safety research, discussing the rhPDGF-bb safety profile and track record of use. We'll specifically discuss the findings related to cancer, including the FDA black box warning! Tune in to understand the compelling evidence regarding the true safety of this powerful regenerative protein.

#PDGF #RegenerativeMedicine #GrowthFactorTherapy #AntiAging #SkinRejuvenation #CollagenBoost #Microneedling #HairRegeneration #CosmeticInnovation #Ariessence #HealingFaster #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Hee CK, Slade HB, Lynch SE. A Review of the Safety of Exogenously Applied Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications. Lynch Regenerative Medicine, LLC; 2025. RPT-001. https://www.lynchregen.com/wp-content/uploads/2025/09/RPT-001v1.0-A-Review-of-the-Safety-of-Exogenously-Applied-rhPDGF-vFinal.pdf

Skinfluenced - The Skin Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Skinfluenced - The Skin Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other66

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other66

PubMed17

Youtube8